KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Interest Expenses (2023 - 2025)

Aurinia Pharmaceuticals' Interest Expenses history spans 3 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 8.64% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $4.3 million, down 10.44%, while the annual FY2025 figure was $4.3 million, 10.44% down from the prior year.
  • Interest Expenses reached $1.0 million in Q4 2025 per AUPH's latest filing, down from $1.1 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.4 million in Q3 2023 to a low of $65000.0 in Q2 2023.
  • Average Interest Expenses over 3 years is $1.1 million, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Interest Expenses: soared 1743.08% in 2024, then decreased 16.84% in 2025.
  • A 3-year view of Interest Expenses shows it stood at $1.3 million in 2023, then decreased by 12.52% to $1.1 million in 2024, then fell by 8.64% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Interest Expenses are $1.0 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025).